Literature DB >> 15328139

Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.

Rama Falk1, Jacob Grunwald, Amnon Hoffman, Abraham J Domb, Itzhack Polacheck.   

Abstract

The pharmacokinetic characteristics and tissue distribution of a novel water-soluble, nontoxic amphotericin B-arabinogalactan (AMB-AG) conjugate exhibited distinct differences from those of micellar and liposomal amphotericin B formulations. These differences included extended persistence of drug in the body and its accumulation in the lungs; thus, the AMB-AG conjugate was highly effective in treating systemic murine aspergillosis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328139      PMCID： PMC514765          DOI： 10.1128/AAC.48.9.3606-3609.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.

Authors:  Jill Adler-Moore; Richard T Proffitt
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 2.  Overview of the lipid formulations of amphotericin B.

Authors:  Bertrand Dupont
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates.

Authors:  T Ehrenfreund-Kleinman; T Azzam; R Falk; I Polacheck; J Golenser; A J Domb
Journal:  Biomaterials       Date:  2002-03       Impact factor: 12.479

Review 4.  Lipid formulations of amphotericin B: recent progress and future directions.

Authors:  J W Hiemenz; T J Walsh
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

5.  Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

Authors:  J R Wingard; P Kubilis; L Lee; G Yee; M White; L Walshe; R Bowden; E Anaissie; J Hiemenz; J Lister
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

6.  Psoralen-containing vinyl monomer for conjugation of double-helical DNA with vinyl polymers.

Authors:  M Maeda; C Nishimura; D Umeno; M Takagi
Journal:  Bioconjug Chem       Date:  1994 Nov-Dec       Impact factor: 4.774

7.  A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.

Authors:  R Falk; A J Domb; I Polacheck
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

8.  Pharmacology, toxicity, and therapeutic usefulness of amphotericin B.

Authors:  W T Butler
Journal:  JAMA       Date:  1966-01-31       Impact factor: 56.272

9.  Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.

Authors:  J Golenser; S Frankenburg; T Ehrenfreund; A J Domb
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

10.  Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.

Authors:  D W Denning; L Hall; M Jackson; S Hollis
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191
View more
  3 in total

1.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.

Authors:  Cristiana T Trinconi; Juliana Q Reimão; Jenicer K U Yokoyama-Yasunaka; Danilo C Miguel; Silvia R B Uliana
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

3.  Amphotericin B-gum arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and fungi.

Authors:  K K Nishi; M Antony; P V Mohanan; T V Anilkumar; P M Loiseau; A Jayakrishnan
Journal:  Pharm Res       Date:  2007-03-20       Impact factor: 4.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.